The secretome of cancer cells is a valuable source of biomarkers that can ultimately reach the serum or other body fluids. Cancer biomarkers can facilitate early diagnosis and monitoring of the disease, contribute to our understanding of tumor biology, and support the development of more efficient therapies. Recently, high-throughput proteomic analysis of the conditioned media of cancer cell lines has shown potential to identify novel biomarkers in cancer. We used two-dimensional gel electrophoresis coupled to liquid chromatography tandem mass spectrometry to identify the secretome of the large cell lung cancer cell lines QU-DB and Mehr-80, which were established from a Canadian and a Persian patient, respectively. A total of 130 distinct protein species were identified. Most of them were previously found in serum or other body fluids, the membrane compartment or conditioned media of other cancer cell lines. Some of the proteins that we identified, e.g. IL-6, triosephosphate isomerase, PGP9.5, a-enolase, Dickkopf-1, and peroxiredoxin-1 have been already known as putative serum markers for lung cancer, whereas others might be candidate markers for further validation in lung cancer body fluids such as IL-25, stathmin, vimentin, peptidyl-prolyl cis-trans isomerase A, transgelin-2, and chloride intracellular channel protein 4.
Introduction
Cancer cell communications are substantially influenced by their secretome, a collection of molecules that are shed (membrane and membrane-bound proteins) or secreted either through classical (proteins with a signal peptide) or nonclassical (intracellular proteins) pathways. The identification of cancer cell secretome has uncovered mechanisms related to angiogenesis, invasion and metastasis, and can contribute to the development of new strategies for the efficient control of cancer. Moreover, secreted or shed proteins can reach body fluids including serum, an ideal sample source for early diagnosis and monitoring of cancer [1] [2] [3] .
The mortality rate is still high in lung cancer. Novel lung cancer serum biomarkers are needed, because those identified to date, such as cancer embryonic antigen and squamous cell carcinoma (SCC) antigen, lack sufficient specificity and sensitivity to serve as an efficient biomarker [1] .
Although serum contains tumor markers, masking low abundant proteins by high abundant albumin Secretome of lung cancer cell lines www.fhc.viamedica.pl and globulins makes serum high-throughput analysis unreliable. To overcome this drawback, proteomic identification of conditioned media of cancer cell lines has recently attracted much attention [1] [2] [3] . Generally, the identified proteins were already known to be involved in cancer development and progression, and subsequent studies validated the presence of several of them in sera from cancer patients. For example, more than 1,000 proteins in conditioned media from four lung cancer cell lines of different histological backgrounds (small-cell lung cancer H1688, adenocarcinoma line H23, SCC cell line H520, and large cell lung carcinoma (LCC) line H460) have been identified. Using different search tools, the most promising candidates for validation in sera were then selected, and increased levels of some of them were confirmed in sera of lung cancer patients [1] .
Based on the size and appearance of the malignant cells, lung cancers are divided into small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC); the latter type accounts for more than 80% of all lung tumors [1] . Among the three major subtypes of NSCLC (adenocarcinoma, SCC and LCC), LCC (9% of all lung cancers) has the poorest prognosis. This poorly differentiated lung cancer consists of large cells with abundant cytoplasm and large nuclei. The neuroendocrine variant of LCC has the worst prognosis [4, 5] .
The secretome of two established LCC cell lines QU-DB and Mehr-80 have not been investigated to date. Cell line QU-DB was established from a primary lung tumor of a 70 year-old man with LCC in Canada, and Mehr-80, a neuroendocrine variant of LCC, was established from the pleural effusion of a 40 year-old woman in Iran [4, 5] . To find novel lung cancer biomarkers, the present study analyzed the conditioned media of the two LCC cell lines using two-dimensional gel electrophoresis (2DE) coupled to mass spectrometry (MS).
Material and methods
Cell culture and preparation of conditioned media. The study was approved by the Ethics Committee of Shiraz University of Medical Sciences. The QU-DB and Mehr-80 LCC cells were purchased from the Pasteur Institute of Iran. They were cultured in 150 cm 2 flasks (Nunc, Roskilde, Denmark) at 37°C (5% CO 2 and 95% air) in RPMI-1640 (Biosera, Ringmer, UK) plus 10% FBS (Biosera), and 100 U/mL penicillin with100 μg/mL streptomycin (Biosera) until they reached 70--80% confluence. The media were then discarded, and the cells washed three times with PBS and incubated in 30 mL RPMI with 8 mM L-glutamine (Sigma-Aldrich, Steinheim, Germany) for another 24 h. The media were collected and centrifuged at 4°C (200 × g, 10 min) to remove debris, followed by sterile filtration by cell culture filters (JET BIO-FIL, Guangzhou, China) with a 0.2 μm pore size. The collected media were frozen at -80°C until use. The cell viability was checked by the trypan blue dye exclusion method.
Each cell line was grown in six batches with 30 mL serum-free medium. Two 30-mL batches were combined for each cell line, then a protease inhibitor cocktail (Roche, Penzberg, Germany) was added to a 1 × final concentration, and the mixture was dialyzed overnight at 4°C using a 3.5-kDa molecular mass cutoff membrane in 10 L of 1 mM ammonium bicarbonate buffer (Sigma) with four solution changes. The dialyzed media were frozen and lyophilized to dryness. Three lyophilized samples per cell line were obtained from the three combinations of two 30-mL portions of media. To prepare the media to be used as a negative control, the above procedure was repeated with the culture media without cells.
After lyophilization, the samples were resuspended in lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 2% immobilized pH gradient (IPG) buffer (pH 3-10) (GE Healthcare, Uppsala, Sweden)), aliquoted and stored at -80°C. The protein concentration was determined by the Bradford protein method and bovine serum albumin (Sigma, Germany) as standard.
Two-dimensional gel electrophoresis.
The first dimensional isoelectric focusing (IEF) was done with the Protean IEF cell system (Bio-Rad, Philadelphia, PA, USA). Approximately 250 μg of the protein sample was applied per IPG strip (pH 3-10 nonlinear, 18 cm) by active rehydration (50 V, 20 C) for 14 h in rehydration buffer (2 M thiourea (Merck, Darmstadt, Germany), 8 M urea, 2% w/v CHAPS, 0.3% wt/vol DTT, 2% vol/vol IPG 3-10 buffer and bromophenol blue) followed by IEF for a total of 90,000 Vh.
After IEF, each strip was equilibrated in 10 mL equilibration buffer (50 mM Tris, pH 8.8, 6 M urea, 30% wt/vol glycerol, 2% wt/vol SDS) containing 65 mM DTT (fist step) and 135 mM idoacetamide (second step) at room temperature for 15 min. Then the equilibrated strips were sealed on the top of two-dimensional 12% polyacrylamide gels with a Protean II xi 2-D Cell (Bio-Rad) at 15 mA/gel for 10 min and then 25 mA/gel until the bromophenol blue dye front reached the bottom of the gels. The gels were visualized with an analytical silver staining technique, scanned with a GS-800 calibrated densitometer (Bio-Rad) and analyzed with Prodigy SameSpots version 1.0 software (Nonlinear Dynamics, Newcastle, UK) according to the manufacturer's instructions. The reagents were purchased from GE Healthcare, Uppsala, Sweden, except where stated.
Liquid chromatography-mass spectrometry (LC-MS/MS).
The spots of interest were picked up from gels that were stained with a preparative MS-compatible silver staining method. For in-gel digestion of proteins, the spots were destained, reduced, alkylated, and finally digested with sequencing grade modified trypsin (Promega, Madison, WI, USA). The resulting peptides were extracted, and lyo- www.fhc.viamedica.pl philized using a vacuum drier. Lyophilized samples were resuspended in 0.1% formic acid (FA) prior to LC-MS/MS analysis. An Agilent 1100 LC/MSD trap XCT was used for HPLC and MS/MS. Solutions used were water/0.1% FA and ACN/0.1% FA. A trap column (G 1375-87320, 105 mm, 25 μm; Agilent, Germany) was connected to a standard column (Zorbax 300 SB-C18, 3.5 μm, 0.3 × 75 mm). Peptides (12 μl) were loaded on a trapping column and desalted. The elution program was 2-60% B for 55 min, 80% B for 8 min and re-equilibration of 2% B for 10 min, for a total run of 78 min. The MS was operated in standard scan mode for MS analysis and in ultra scan mode for MS/MS analysis. The MS/MS data was analyzed with the Spectrum Mill database search engine (Agilent, Palo Alto, CA, USA) against the Swiss-Prot database (released May, 2010).
Results
We used 2DE and LC-MS/MS to identify proteins in the conditioned media of the LCC cell lines QU-DB and Mehr-80. To reduce the likelihood of intracellular protein contamination, the secretome were collected from 24-h serum-free culture media because the trypan blue exclusion test showed a low rate of cell death (less than 2%) over 24 h. Three gels were run for each cell line, and the similarity of gels was found to be more than 80%. Collectively, 395 reproducible, distinct, intense spots were excised from all gels. Of these 395 spots, 141 were found in the conditioned media of both cell lines, of which 116 were identified by MS. For 96 of the 116 spots, MS was done in just one cell line, but for 20 of them (spots 2-4, 24, 25, 29, 34, and 35 in Table 1 , and 64, 65, 68, 86, 100, 102, 112, 115, 116, 132-134 in Supplementary File 1), MS was done in both cell lines to establish that spots with the same position in gels from each cell line represented the same polypeptide. Seventytwo of the 395 spots were hardly-visible/invisible on Mehr-80 gels, and 41 were hardly-visible/invisible on QU-DB gels. Of these unique spots, 39 were identified by MS analysis.
The identified proteins were related to 130 protein species that were essentially involved in protein folding, the cytoskeleton, signal transduction, cell growth, metabolism and redox regulation (Table 1 and Supplementary File 1) . By searching in Swiss-Prot and published articles, the majority of proteins were found to have been previously detected in body fluids, the conditioned media of cancer cell lines, and/or related to the cell membrane in humans . Each of these proteins was usually present in more than one of these locations. Of them, 38 were already found in serum or other body fluids in pathological conditions (Table 1) . Their descriptions and positions on gels are displayed in Table 1 and Figure 1 . Other proteins, which were essentially related to cell membrane/membrane-bound or common to those in prior publications on cancer cell secretome [3] , are listed in Table 2 (Supplementary File 1).
Discussion
To identify candidate extracellular biomarkers for lung cancer, the conditioned media of QU-DB and Mehr-80 LCC cell lines were subjected to 2DE and MS analysis. Most of the 130 identified proteins were already found in body fluids/in vivo tumor microenvironment, conditioned media of other cancer cell lines, or related to the cell membrane in humans , the locations supporting the possibility that a protein might be secreted or shed. It is known that some intracellular proteins, particularly those with increased concentrations in body fluids, may be secreted by a variety of mechanisms such as exocytosis of secretory vesicles or exomes [1, 3, 11] . Despite optimized cell confluence and incubation times during media preparation, the presence of some of the intracellular proteins in conditioned media probably resulted from cell death.
Fifteen of the identified proteins in conditioned media of QU-DB and Mehr-80, e.g. IL-6, triosephosphate isomerase, PGP9.5, high mobility group protein B1, Dickkopf-1, and peroxiredoxin-1 were already known to be putative serum markers for lung cancer [1, 2, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Twenty three of the identified proteins have been previously found in human body fluids or the in vivo tumor microenvironment in pathological conditions other than lung cancer (Table 1) [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , indicating that they might be products of cellular secretion. Among them, those known to be overexpressed in lung cancer such as 78-kDa glucose-regulated protein [14] , epidermal fatty acid-binding protein [36] , transgelin-2 [37] , hsp27 [38] , stress-induced phosphoprotein 1 [38] , vimentin [39] , and transketolase [40] may be more appropriate candidate biomarkers for further validation in body fluids from lung cancer patients.
In the conditioned media of the QU-DB and Mehr-80, in addition to IL-6, we also found two members of the cytokine family with classical signal peptides for secretion: ILE1 and IL-25 [34, 35] . The former is associated with epithelial-to-mesenchymal transition and metastasis in breast cancer [34] , whereas the latter is a mediator of type-2 immune responses. Moreover, IL-25 was reported to have a pathogenic role in allergic lung diseases, and was up-regulated in nasal lavage fluid [35] . It has been shown that epithelial cells, myeloid cells, eosinophils, basophils and mast cells produce IL-25 [35] , and its presence in conditioned media of several cancer cell lines including lung has recently been reported [3] . Membrane/membrane-bound proteins can be released into body fluids and serve as valuable serum biomarkers, e.g. carcinoembryonic antigen in lung cancer [1] . Some of the proteins we have identified belong to this category. Examples of those which are overexpressed in lung cancer and which deserve further attention are annexin1 [14] , T complex protein, [38] and transketokase [40] .
Most of the proteins identified in this study have been reported to be present in media used to grow human cancer cell lines [1] [2] [3] 11] . Several of them, e.g. stathmin, are overexpressed in lung cancer. Stathmin provokes microtubule depolymerisation and regulates microtubule-dependent processes including cell division and motility. Its overexpression has been linked to cell migration and invasion in lung adenocarcinoma and SCC [41] . Glutathione S-transferase omega-1 [11] , and chloride intracellular channel protein 4 (CLIC4) [11] have been found in lung cancer cell line media compared to media derived from nor-Secretome of lung cancer cell lines www.fhc.viamedica.pl mal lung tissue cell cultures, and the search for these proteins in serum may be worthwhile.
It remains to be determined whether our candidate biomarkers are found in all types of lung cancer, or are restricted to LCC. Because NSCLC studies usually focus on SCC and adenocarcinoma, the current data is insufficient to judge their specificity to LCC. Among proteins identified in this study, lactate dehydrogenase-B, a-enolase, IL-6, hsp-27, stress-induced phosphoprotein 1, plasminogen activator inhibitor 1, vimentin, T-complex protein 1, and isocitrate dehydrogenase 1 were investigated in LCC [10, 38, 39, 42] . They were found to be significantly overexpressed in adenocarcinoma and SCC subtypes in addition to LCC. For vimentin and IL-6, there are reports to show their increases in LCC compared to other types of NSCLC [10, 39] . Vimentin, an intermediate filament protein, usually expressed in mesenchymal cells, plays a role in cell movement. Vimentin is a marker for epithelial to mesenchymal transition, a process that has been critically linked to cancer invasiveness [17] . Interestingly, the highest percentage of vimentin positivity has been observed in LCC compared to other subtypes of NSCLC (SCC and adenocarcinoma) and SCLC [39] .
In conclusion, we searched for potential biomarkers of lung cancer in conditioned media from two lung cancer cell lines. Some of the identified proteins were already suggested as being putative serum biomarkers for lung cancer, i.e. PGP9.5 and IL-6. Others, such as IL-25, stathmin, vimentin, epidermal fatty acidbinding protein, transgelin-2, stress-induced phosphoprotein 1 and CLIC4, should be further investigated as possible biomarkers of LCC.
